Evidence map›Paper›PMID 39830651›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Efficacy of Clindamycin in Preventing Abortion and Vertical Transmission of

Mitra Sadeghi, Seyed Abdollah Hosseini, Shahabeddin Sarvi, Pedram Ebrahimnejad, Hossein Asgarian Omran, Zohreh Zare, Shirzad Gholami, Alireza Khalilian, Mostafa Tork, Ahmad Daryani and 1 more

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mitra SadeghiToxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Seyed Abdollah HosseiniToxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-2990-1123
Shahabeddin SarviToxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-3412-1033
Pedram EbrahimnejadDepartment of Medicinal, Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Hossein Asgarian OmranDepartment of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0003-3816-8792
Zohreh ZareDepartment of Anatomical Sciences, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Shirzad GholamiToxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0003-2429-7702
Alireza KhalilianDepartment of Biostatistics, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0001-7463-1188
Mostafa TorkToxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Ahmad DaryaniToxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0001-8571-5803
Sargis A AghayanLaboratory of Molecular Parasitology, Scientific Center of Zoology and Hydroecology, Yerevan, Armenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Objectives: Consequently, in search of an effective treatment, for the first time in Iran, the effectiveness of clindamycin in preventing abortion and vertical transmission of the PRU strain of Methods: On the twelfth day of gestation, pregnant mice were exposed to Results: The findings showed a significant reduction in the number of cysts in the eye and brain (ranging from 77.32% to 90.72%) among the groups treated with clindamycin and spiramycin compared to the control group. Furthermore, treatment with clindamycin, like treatment with spiramycin, was able to suppress inflammatory changes, prevent cell death, and reduce vascular cuffs in the brain, as well as decrease bleeding, placental thrombosis, and the accumulation of inflammatory cells in the placenta. Clindamycin was also effective in diminishing retinal folds, tiny retinal bleeds, and cell vacuolation in eye tissues. Immunologically, treatment in both the spiramycin and clindamycin groups resulted in a decrease in the level of the cytokine TNF-α, indicating an increase in the cellular immune response. In addition, increased levels of IL-10 in the treated infected groups could contribute to the reduction of TNF-α production. Conclusions: Typically, spiramycin is the first choice for treating congenital toxoplasmosis, but clindamycin can be a useful substitute or additional treatment when resistance to primary medications occurs, when there is intolerance, or when access to the main drugs is restricted.

Indexed as

ClindamycinCongenitalIn VivoPru StrainToxoplasma gondii

Identifiers

PMID39830651
PMCPMC11742104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.